Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at OncoCyte Corp fell by 12.07m. Cash Flow from Financing totalled 12.19m or 810.78% of revenues. In addition the company used 23.33m for operations while cash used for investing totalled 932.00k.
Cash flow per share | -3.69 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.70 |
---|---|
Tangible book value per share | -2.53 |
More ▼
Balance sheet in USDView more
Current ratio | 1.38 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0216 |
---|---|
Total debt/total capital | 0.0212 |
More ▼